2024-08-01 2025-07-31 2025-07-31 false 08949503 EXTENTUS PHARMA LTD 72110Research and experimental development on biotechnology iso4217:GBP xbrli:pure 089495032024-08-01 089495032025-07-31 089495032024-08-01 2025-07-31 08949503bus:SmallEntities2024-08-01 2025-07-31 08949503bus:AuditExempt-NoAccountantsReport2024-08-01 2025-07-31 08949503bus:FullAccounts2024-08-01 2025-07-31 08949503core:WithinOneYear2025-07-31 08949503core:AfterOneYear2025-07-31 08949503core:WithinOneYear2024-08-01 2025-07-31 08949503core:AfterOneYear2024-08-01 2025-07-31 08949503core:CurrentFinancialInstruments2025-07-31 08949503core:Non-currentFinancialInstruments2025-07-31 08949503core:CurrentFinancialInstruments2024-08-01 2025-07-31 08949503core:Non-currentFinancialInstruments2024-08-01 2025-07-31 08949503core:LandBuildings2024-08-01 2025-07-31 08949503core:FurnitureFittings2024-08-01 2025-07-31 08949503core:OfficeEquipment2024-08-01 2025-07-31 08949503core:Vehicles2024-08-01 2025-07-31 08949503core:PlantMachinery2024-08-01 2025-07-31 08949503core:OtherPropertyPlantEquipment2024-08-01 2025-07-31 08949503core:LandBuildings2025-07-31 08949503core:PlantMachinery2025-07-31 08949503core:Vehicles2025-07-31 08949503core:FurnitureFittings2025-07-31 08949503core:OfficeEquipment2025-07-31 08949503core:OtherPropertyPlantEquipment2025-07-31 08949503core:Right-of-useAssets2024-08-01 2025-07-31 08949503core:Right-of-useAssets2025-07-31 08949503core:Goodwill2024-08-01 2025-07-31 08949503core:PatentsTrademarksLicencesConcessionsSimilar2024-08-01 2025-07-31 08949503core:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-08-01 2025-07-31 08949503core:OtherResidualIntangibleAssets2024-08-01 2025-07-31 08949503core:Goodwill2025-07-31 08949503core:DevelopmentCostsCapitalisedDevelopmentExpenditure2025-07-31 08949503core:PatentsTrademarksLicencesConcessionsSimilar2025-07-31 08949503core:OtherResidualIntangibleAssets2025-07-31 08949503dpl:CostSales2024-08-01 2025-07-31 08949503dpl:AdministrativeExpenses2024-08-01 2025-07-31 08949503dpl:DistributionCosts2024-08-01 2025-07-3108949503core:ShareCapital2025-07-31 08949503core:SharePremium2025-07-31 08949503core:RevaluationReserve2025-07-31 08949503core:OtherReservesSubtotal2025-07-31 08949503core:ShareCapitalPreferenceShares2025-07-31 08949503core:CapitalRedemptionReserve2025-07-31 08949503core:OtherCapitalReserve2025-07-31 08949503core:RetainedEarningsAccumulatedLosses2025-07-3108949503core:ShareCapital2024-08-01 2025-07-31 08949503core:SharePremium2024-08-01 2025-07-31 08949503core:RevaluationReserve2024-08-01 2025-07-31 08949503core:OtherReservesSubtotal2024-08-01 2025-07-31 08949503core:RetainedEarningsAccumulatedLosses2024-08-01 2025-07-310894950312024-08-01 2025-07-31 0894950322024-08-01 2025-07-3108949503core:ShareCapital12024-08-01 2025-07-31 08949503core:ShareCapital22024-08-01 2025-07-3108949503core:SharePremium12024-08-01 2025-07-31 08949503core:SharePremium22024-08-01 2025-07-3108949503core:RevaluationReserve12024-08-01 2025-07-31 08949503core:RevaluationReserve22024-08-01 2025-07-3108949503core:RetainedEarningsAccumulatedLosses12024-08-01 2025-07-31 08949503core:RetainedEarningsAccumulatedLosses22024-08-01 2025-07-310894950312024-08-01 2025-07-3108949503core:Non-currentFinancialInstrumentscore:CostValuation2024-08-01 08949503core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-07-31 08949503core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-07-31 08949503core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-07-31 08949503core:Non-currentFinancialInstrumentscore:TransfersIntoOrOutInvestmentsIncreaseDecreaseInInvestments2025-07-31 08949503core:Non-currentFinancialInstrumentscore:CostValuation2025-07-3108949503core:Non-currentFinancialInstrumentscore:ProvisionsForImpairmentInvestments2024-08-01 08949503core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-07-31 08949503core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-07-31 08949503core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-07-31 08949503core:Non-currentFinancialInstrumentscore:FurtherSpecificIncreaseDecreaseInProvisionsForImpairmentInvestments1ComponentCorrespondingTotal2025-07-31 08949503core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-07-31 08949503core:Non-currentFinancialInstrumentscore:ProvisionsForImpairmentInvestments2025-07-3108949503core:Non-currentFinancialInstruments2025-07-31 08949503core:Non-currentFinancialInstruments2024-07-31089495032023-08-01 089495032024-07-31 089495032023-08-01 2024-07-31 08949503core:WithinOneYear2024-07-31 08949503core:AfterOneYear2024-07-31 08949503core:CurrentFinancialInstruments2024-07-31 08949503core:Non-currentFinancialInstruments2024-07-31 08949503core:LandBuildings2024-07-31 08949503core:PlantMachinery2024-07-31 08949503core:Vehicles2024-07-31 08949503core:FurnitureFittings2024-07-31 08949503core:OfficeEquipment2024-07-31 08949503core:OtherPropertyPlantEquipment2024-07-31 08949503core:Right-of-useAssets2024-07-31 08949503core:Goodwill2024-07-31 08949503core:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-07-31 08949503core:PatentsTrademarksLicencesConcessionsSimilar2024-07-31 08949503core:OtherResidualIntangibleAssets2024-07-31 08949503dpl:AdministrativeExpenses2023-08-01 2024-07-3108949503core:ShareCapital2024-07-31 08949503core:SharePremium2024-07-31 08949503core:RevaluationReserve2024-07-31 08949503core:OtherReservesSubtotal2024-07-31 08949503core:ShareCapitalPreferenceShares2024-07-31 08949503core:CapitalRedemptionReserve2024-07-31 08949503core:OtherCapitalReserve2024-07-31 08949503core:RetainedEarningsAccumulatedLosses2024-07-3108949503core:RetainedEarningsAccumulatedLosses2023-08-01 08949503core:ShareCapital2023-08-01 08949503core:SharePremium2023-08-01 08949503core:RevaluationReserve2023-08-01 08949503core:ShareCapital2023-08-01 2024-07-31 08949503core:SharePremium2023-08-01 2024-07-31 08949503core:RevaluationReserve2023-08-01 2024-07-31 08949503core:OtherReservesSubtotal2023-08-01 2024-07-31 08949503core:RetainedEarningsAccumulatedLosses2023-08-01 2024-07-310894950312024-08-01 2025-07-31 0894950312025-07-3108949503bus:Director12024-08-01 2025-07-3108949503bus:Director22024-08-01 2025-07-3108949503bus:Director32024-08-01 2025-07-3108949503bus:Director42024-08-01 2025-07-3108949503bus:PrivateLimitedCompanyLtd2024-08-01 2025-07-31
EXTENTUS PHARMA LTD
Unaudited Financial Statements
for the year ended 31 July 2025
(formerly TANDEM NANO LTD)
Company registration number 08949503
(England and Wales)

Company Information

For the year ended 31 July 2025
Directors Broughton, Nicola Ann
Odell, Antony Ruben
Nolan, Emma
Owen, Andrew

Company secretary Bickerstaff, Roger

Registered office 11b Liverpool Science Park Ic1
Mount Pleasant
Liverpool
L3 5TF

Registered number 08949503

Accountant FACT3
2nd Floor, 3 Hardman Square
Spinningfields
Manchester
Greater Manchester
M3 3EB

Statement of Financial Position

As at 31 July 2025
Notes
2025
2024
£
£
£
£
Current assets
Debtors
4
23,844
29,406
Cash at bank and in hand
200,212
230,912
224,056
260,318
Creditors
Amounts falling due within one year
5
(901,722)
(883,354)
(901,722)
(883,354)
Net current assets (liabilities)
(677,666)
(623,036)
Total assets less current liabilities
(677,666)
(623,036)
Creditors
Amounts falling due after one year
6
(665,347)
(665,348)
(665,347)
(665,348)
Net assets (liabilities)
(1,343,013)
(1,288,384)
Capital and reserves
Called up share capital
75
75
Profit and loss account
(1,343,088)
(1,288,459)
Total equity
(1,343,013)
(1,288,384)

The company is a private company limited by shares and registered in England and Wales. It was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
With effect from 6 November 2025, the name of the Company was changed from TANDEM NANO LTD to EXTENTUS PHARMA LTD .
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.
The financial statements have been prepared in accordance with the special provisions applicable to companies subject to the small companies regime.
The directors have chosen to not file a copy of the company's profit and loss account under section 444 (5A) of the Companies Act 2006.

The financial statements were approved and authorised for issue by the Board of Directors on 29 April 2026 and are signed on its behalf by:

Broughton, Nicola Ann
Broughton, Nicola Ann
Director

Company registration number 08949503

Notes to the Financial Statements

For the year ended 31 July 2025

1. Statutory information

The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The financial statements are presented in sterling and this is the functional currency of the company.

2. Accounting policies

2.1. Basis of preparation

The financial statements have been prepared in accordance with FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.

The financial statements have been prepared under the historical cost convention in accordance with the Companies Act 2006.

2.2. Going concern

The Directors have prepared detailed financial forecasts and cash flows looking beyond 12 months from the date of the approval of these financial statements. In developing these forecasts, the Directors have made assumptions based upon their view of the current and future economic conditions that will prevail over the forecast period.


The Directors estimate that the cash held by the company together with fund raise expectations, will be sufficient to support the current, and expected, level of activities. Accordingly, they have continued to adopt the going concern basis in preparing these financial statements.

2.3. Turnover

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

2.4. Pensions

Defined contribution pension plan

The company operates a defined contribution pension plan for the benefit of its employees. Contributions are recognised as expenses as they become payable. Differences between contributions payable in the year and those actually paid are recognised as either prepayments or accruals in the balance sheet. The assets of the defined contribution pension scheme are held separately from those of the company in an independently administered fund.

2.5. Current taxation

Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.


Current or deferred taxation assets and liabilities are not discounted.


Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

2.6. Deferred tax

Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.

3. Employees

The average number of employees during the year was 3 (2024: 2).

4. Debtors

2025
2024
£
£
Other debtors
23,437
28,999
Prepayments and accrued income
407
407
Total due within one year
23,844
29,406
Total due after one year
-
-
Total
23,844
29,406

5. Creditors due within one year

2025
2024
£
£
Trade creditors
854,078
735,304
Other creditors
312
312
Taxation and social security
3,181
53
Accruals and deferred income
44,151
147,685
Total
901,722
883,354

6. Creditors due after one year

2025
2024
£
£
Other creditors
665,347
665,348
Total
665,347
665,348

Unsecured convertible loans are not subject to any interest and have a maturity date of 10 years being April 2029. The unsecured convertible loan balance will convert into the most senior class of shares in the capital of the Company upon a qualifying event, at a pre-defined conversion rate calculated from the latest equity investment price and discounted as per the terms of the agreement.